Stockreport

Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

Keros Therapeutics, Inc. - common stock  (KROS) 
PDF LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focus [Read more]